Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Masuda N, et al. Among authors: kurebayashi j. Cancer Chemother Pharmacol. 2008 May;61(6):989-95. doi: 10.1007/s00280-007-0555-z. Epub 2007 Jul 20. Cancer Chemother Pharmacol. 2008. PMID: 17641893 Clinical Trial.
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: kurebayashi j. J Cancer Res Clin Oncol. 2008 May;134(5):561-7. doi: 10.1007/s00432-007-0319-5. Epub 2007 Oct 16. J Cancer Res Clin Oncol. 2008. PMID: 17938960
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: kurebayashi j. Cancer Lett. 2008 Jun 8;264(1):44-53. doi: 10.1016/j.canlet.2008.01.015. Epub 2008 Feb 15. Cancer Lett. 2008. PMID: 18280644
Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Miyoshi Y, et al. Among authors: kurebayashi j. Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Breast Cancer. 2010. PMID: 19657712 Review.
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T. Shiba E, et al. Among authors: kurebayashi j. Breast Cancer. 2016 May;23(3):499-509. doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6. Breast Cancer. 2016. PMID: 25655898 Free PMC article. Clinical Trial.
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T. Ohashi Y, et al. Among authors: kurebayashi j. Support Care Cancer. 2018 Mar;26(3):933-945. doi: 10.1007/s00520-017-3914-2. Epub 2017 Oct 24. Support Care Cancer. 2018. PMID: 29063390 Free PMC article. Clinical Trial.
Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study.
Kurebayashi J, Yamamoto Y, Tanaka K, Kohno N, Kurosumi M, Moriya T, Nishimura R, Ogawa Y, Taguchi T; Tumor Marker Study Group of the Japanese Breast Cancer Society, Japan. Kurebayashi J, et al. Breast Cancer. 2003;10(1):38-44. doi: 10.1007/BF02967624. Breast Cancer. 2003. PMID: 12525762
The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S. Kim SJ, et al. Among authors: kurebayashi j. Cancer Lett. 2014 Dec 28;355(2):217-23. doi: 10.1016/j.canlet.2014.08.042. Epub 2014 Sep 10. Cancer Lett. 2014. PMID: 25218592
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y. Kurebayashi J, et al. Breast Cancer. 2021 May;28(3):684-697. doi: 10.1007/s12282-020-01205-w. Epub 2021 Feb 27. Breast Cancer. 2021. PMID: 33638810 Free PMC article. Clinical Trial.
168 results